A client of NanoGuardianTM, a division of NanoInk® has been issued approval by the Food and Drug Administration (FDA) to use NanoGuardian's cutting edge NanoEncryptionTM technology as an on-dosage, brand protection technology. NanoGuardian's NanoEncryption technology provides pharmaceutical manufacturers with true forensic, multi-layered, authentication and tracing brand protection at the individual dosage level.
"FDA approval of our NanoEncryption technology is an important milestone for public health and the continued fight to secure the pharmaceutical supply chain," said James M. Hussey, CEO, NanoInk. "This novel technology is virtually impossible to copy and creates an impenetrable barrier to reverse engineering by counterfeiters. Not only will NanoGuardian help protect the pharmaceutical supply chain, but we also see additional applications for many other product categories that are threatened by illegal diversion and counterfeiting."
NanoGuardian's NanoEncryption technology works directly on tablets, capsules and vials and captures a virtually unlimited amount of data including manufacturing information, dosage strength, expiration date, and the targeted site of distribution including country, state and specific distributor if desired. NanoGuardian's NanoEncryption technology is complementary to on-package brand protection options such as RFID and 2-D Barcodes, providing a multi-layered, protective approach for each individual dose from plant to patient.
According to a 2006 report from the World Health Organization, an estimated $40 billion in counterfeit pharmaceuticals and an additional $15 billion in diverted products enter the pharmaceutical supply chain each year causing harmful and at times devastating consequences for many patients and their families.